Navigation Links
Immunosyn Announces Biozyme Lab's Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
Date:11/28/2007

LA JOLLA, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN) today announced that Biozyme Laboratories has received approval from the MHRA to import base material and manufacture SF-1019 for human use in clinical trials. SF-1019 is a biopharmaceutical for which Immunosyn holds the exclusive license for worldwide marketing rights.

The "Medicines and Healthcare products Regulatory Agency," more commonly known as the MHRA, functions in the United Kingdom on behalf of the European Medicines Agency (EMEA) much like the FDA does in the United States. MHRA regulates which drugs are safe and effective for use in humans to treat specific ailments and conditions. The license approvals currently granted by the MHRA include a "Manufacturer's Authorisation -- Investigational Medicinal Products" (MIA(IMP)) as well as "Manufacturer's / Importer's Licence" (MIA) for manufacturing investigational medicinal products for use in humans for phase I, II and III clinical trials. If a company successfully completes these trials it can apply for a full license to distribute throughout the European Union.

"The fact that SF-1019 has garnered manufacturing and import approval from the MHRA so rapidly is exciting news," says Stephen D. Ferrone, CEO and President of Immunosyn, "as every milestone we achieve in this process brings us that much closer to producing revenue for our shareholders."

"This is another example whereby Immunosyn's shareholders strongly benefit from our unique relationship with our largest shareholder, Argyll Biotechnologies," stated David Criner, CFO of Immunosyn. "Under the terms of our exclusive license agreement, Argyll Biotechnologies is responsible for all regulatory approvals and clinical trials including those required by the MHRA and FDA together with their associated costs."

Under EMEA requirements, in order to obtain approval to manufacture a drug for use in humans, whether for clinical tr
'/>"/>

SOURCE Immunosyn Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Immunosyn Corporation Releases SF-1019 Study Results
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Tasly Pharmaceuticals, Inc., the world,s ... announced today the launch of Deepure. ... address men and women concerned with supporting their ... old age while helping keep their health care ... and herb-based formulas, namely, ProHeart PLUS, ImmunoPower PLUS, ...
(Date:9/30/2014)... 2014  Decision Resources Group finds that the markets ... , Russia , ... (BRIC) will see robust expansion as these economies expand ... procedures. Although revenues will be somewhat impeded by poor ... approval times and demand for low-cost products, the market ...
(Date:9/30/2014)... --  Easy Breathe , the fastest growing online ... now offers the revolutionary AirSense CPAPs by ... apnea therapy devices with internal cellular modems.  This break-through ... share real-time data on each user,s quality of sleep ... addition, the internal modem allows the CPAP to be ...
Breaking Medicine Technology:Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... startup  PhotOral™  announced today it has licensed a ... to develop a novel intraoral device that uses ... dental plaque microorganisms. The agreement empowers ... the $7 billion oral care market.  PhotOral Founder ...
... R.I., Dec. 15, 2011  CVS Caremark announced today ... Chain Distinction Award North America in the Logistics ... week at the annual Supply Chain Logistics Summit ... http://photos.prnewswire.com/prnh/20090226/NE75914LOGO ) The Logistics Best ...
Cached Medicine Technology:Life Sciences Startup PhotOral Licenses Patented Oral Blue-Light Technology From Forsyth Institute 2CVS Caremark Receives Logistics Best Practice Award at 2011 Supply Chain Logistics Summit 2CVS Caremark Receives Logistics Best Practice Award at 2011 Supply Chain Logistics Summit 3
(Date:9/30/2014)... Research by UC Irvine immunologists reveals new information ... a vital process that determines how the body,s ability ... of Nature Immunology , neurology professor Dr. Michael ... Immunology colleagues describe a critical mechanism underlying how T ... , A T cell is a type of blood ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... by Blue Star Nutraceuticals designed to help maximize lean, ... that optimizes the body’s absorption of glucose has caught ... , “The main purpose behind Glycodrive is to ... builds lean muscle,” reports Michaels. “Carbs are essential in ...
(Date:9/30/2014)... Elevate , the latest product from ... and out of the gym by providing natural ingredients that ... of Shane Michaels, prompting an investigative review. , “When ... most people simply just don’t have the ability to perform ... work, getting the motivation to finish a project, or even ...
(Date:9/30/2014)... For most families, fall means back-to-school pictures and ... annual festival. For millions of children, fall also means ... infection Enterovirus D68. , While symptoms mimic the ... especially children with weakened immune systems – can develop ... prompting hospitals across the country to enact visitor restrictions. ...
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set to open ... RMS welcomes the launch of an entirely new facility, ... new treatment center for the Lung Institute. , ... Nashville, the hope is to bring awareness to those ... undiagnosed. With Nashville being a hub for medical technology, ...
Breaking Medicine News(10 mins):Health News:UCI study uncovers important process for immune system development 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:As Hospitals Combat Enterovirus Outbreaks, Patients and Families Turn to “Virtual Visits” with CaringBridge 2Health News:Regenerative Medicine Solutions Expanding 2
... , , BALTIMORE, ... groups and industry to educate expecting parents about the medical significance ... three out of every four pregnant women still consider themselves only ... on stem cell science and policy found that a proprietary, web-based ...
... ROCHESTER, N.Y., Sept. 23 Bausch & Lomb, the ... J. Palmisano have joined its board of directors. , , ... and relevant experience," said Gerald M. Ostrov, chairman and chief executive ... positioned for long-term growth. We welcome Kerry and Bob and look ...
... PLAINS, N.Y., SEPT. 23, 2009 -- Pregnant women should be ... the vaccines become available this year to protect them against ... to eight leading national maternal and infant health organizations. ... College of Obstetricians and Gynecologists, the American Academy of Pediatrics, ...
... Agent-based models (ABMs) are powerful computer-simulation modeling techniques ... of biological phenomena, such as tumor growth, the ... through a population. Researchers will gather Dec. ... Biological Synthesis (NIMBioS) on the University of Tennessee, ...
... , ... for November 17-19, 2009, in Miami, FL , ... Portland, Maine (PRWEB) September 23, 2009 -- IntertechPira and ... 2009, the industry,s leading event focusing on biotechnology, engineering and alternative energy applications as ...
... WAYNE, Pa., Sept. 23 RRY Publications announced the preliminary ... the premier gathering of stem cell company executives, scientists and ... The Summit is an intensive one-day event where attendees explore ... stem cell product commercialization, and the latest investment opportunities within ...
Cached Medicine News:Health News:Data Released at an International Stem Cell Meeting Highlights Effectiveness of New Patient Education System Developed to Support Federal and State Guidelines on Cord Blood Education 2Health News:Data Released at an International Stem Cell Meeting Highlights Effectiveness of New Patient Education System Developed to Support Federal and State Guidelines on Cord Blood Education 3Health News:R. Kerry Clark and Robert J. Palmisano Join Bausch & Lomb Board of Directors 2Health News:Pregnant women need flu shots 2Health News:Agenda Announced for Ionic Liquids 2009 2Health News:5th Annual Stem Cell Summit Set for Feb. 16 in New York City 2Health News:5th Annual Stem Cell Summit Set for Feb. 16 in New York City 3